Tilray Brands, Inc. (TLRY) Ascends While Market Falls: Some Facts to Note
Werte in diesem Artikel
In the latest trading session, Tilray Brands, Inc. (TLRY) closed at $1.26, marking a +1.61% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.29%. At the same time, the Dow lost 0.37%, and the tech-heavy Nasdaq lost 0.34%. Heading into today, shares of the company had lost 14.48% over the past month, lagging the Medical sector's loss of 0.33% and the S&P 500's gain of 3.08%.Market participants will be closely following the financial results of Tilray Brands, Inc. in its upcoming release. It is anticipated that the company will report an EPS of -$0.03, marking a 25% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $206.83 million, up 3.39% from the prior-year quarter. For the full year, the Zacks Consensus Estimates project earnings of -$0.11 per share and a revenue of $877.28 million, demonstrating changes of -1200% and +6.81%, respectively, from the preceding year. It is also important to note the recent changes to analyst estimates for Tilray Brands, Inc. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.59% lower within the past month. Tilray Brands, Inc. currently has a Zacks Rank of #3 (Hold). The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 106, positioning it in the top 43% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tilray Brands, Inc. (TLRY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Tilray (ex Aphria) und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf note
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf note
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Tilray (ex Aphria)
Analysen zu Tilray (ex Aphria)
Datum | Rating | Analyst | |
---|---|---|---|
14.08.2019 | Tilray Buy | The Benchmark Company | |
05.06.2019 | Tilray Perform | Oppenheimer & Co. Inc. | |
15.05.2019 | Tilray Market Perform | BMO Capital Markets | |
21.02.2019 | Aphria Buy | Seaport Global Securities | |
21.02.2019 | Tilray Neutral | Seaport Global Securities |
Datum | Rating | Analyst | |
---|---|---|---|
14.08.2019 | Tilray Buy | The Benchmark Company | |
15.05.2019 | Tilray Market Perform | BMO Capital Markets | |
21.02.2019 | Aphria Buy | Seaport Global Securities | |
16.10.2018 | Tilray Buy | The Benchmark Company |
Datum | Rating | Analyst | |
---|---|---|---|
05.06.2019 | Tilray Perform | Oppenheimer & Co. Inc. | |
21.02.2019 | Tilray Neutral | Seaport Global Securities |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Tilray (ex Aphria) nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen